Evidence of Stavudine-Related Phenotypic Resistance Among Zidovudine-Pretreated HIV-1–Infected Subjects Receiving a Therapeutic Regimen of Stavudine Plus Lamivudine
- 1 September 1999
- journal article
- letter
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 22 (1) , 101-3
- https://doi.org/10.1097/00042560-199909010-00013
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trialThe Lancet, 1999
- Simultaneous vs Sequential Initiation of Therapy With Indinavir, Zidovudine, and Lamivudine for HIV-1 InfectionJAMA, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Randomised placebo-controlled trial of ritonavir in advanced HIV-1 diseaseThe Lancet, 1998
- Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trialThe Lancet, 1997
- A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic MillimeterNew England Journal of Medicine, 1996
- Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individualsThe Lancet, 1996
- Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USAPublished by American Medical Association (AMA) ,1996
- Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and ZalcitabineNew England Journal of Medicine, 1996
- Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination TherapyScience, 1995